Similarly, we found no differences for those under anti-TNF-alpha drugs (median of those treated at T2 139.7 AU/mL; IQR, 61–279) for the subgroups of RA and PsA/Psoriasis, or for those treated with biologicals different from TNF-alpha inhibitors (ustekinumab, secukinumab, abatacept, tocilizumab and vedolizumab) (p > 0,05), csDMARDs (supplementary materials, Table S2), or for other drugs (interferon, colchicine, Jak-inhibitors, belimumab and dimethyl fumarate); (for all at T1, T2 T3; comparison drug vs. no drug). Here, TNF is linked to psoriasis.